Compugen's CEO discusses Q2 2012 results - Earnings call transcript (SeekingAlpha) - Aug 7, 2012 - CGEN-15001 could be safer therapy with reduced risk of infection vs. significant risk posed by approved biologics for autoimmune diseases; Anticipated presentation at the European Congress of Immunology in Sep 2012
Preclinical • Immunology • Inflammatory Bowel Disease • Multiple Sclerosis • Rheumatoid Arthritis
|
|
This was demonstrated for CGEN-15001 in a viral infection model where treatments with CGEN-15001 did not result in exasperation of the viral infections, so the general immune system was capable of fighting the infection. This is in contrast to reported exasperation duration in the same model of derived viral infection by CTL lympho IG [ph] and last version of the rheumatoid arthritis drug, Orencia, currently one of the leading treatments of rheumatoid arthritis.
This demonstrated absence of global immune suppression by CGEN-15001 should lead to a safer therapy with reduced risk of infection as opposed to the significant risk posed by approved biologics for autoimmune diseases. CGEN-15001 will be the subject of the presentation by Professor Joseph Podojil from Professor Miller [ph] of Northwestern University lab at the European Congress of Immunology this September in Glasgow....
(IR 5)
|